NYSE:EBS - Emergent Biosolutions Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $59.27 +0.24 (+0.41 %) (As of 08/20/2018 02:41 AM ET)Previous Close$59.27Today's Range$58.56 - $59.4852-Week Range$34.56 - $60.00Volume238,117 shsAverage Volume331,743 shsMarket Capitalization$2.75 billionP/E Ratio31.19Dividend YieldN/ABeta1.2 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland. Receive EBS News and Ratings via Email Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNYSE:EBS CUSIP29089Q10 Webwww.emergentbiosolutions.com Phone240-631-3200 Debt Debt-to-Equity Ratio0.01 Current Ratio5.59 Quick Ratio4.15 Price-To-Earnings Trailing P/E Ratio31.19 Forward P/E Ratio25.44 P/E Growth1.18 Sales & Book Value Annual Sales$560.87 million Price / Sales5.29 Cash Flow$3.0148 per share Price / Cash19.66 Book Value$18.47 per share Price / Book3.21 Profitability EPS (Most Recent Fiscal Year)$1.90 Net Income$82.59 million Net Margins16.55% Return on Equity15.09% Return on Assets11.91% Miscellaneous Employees1,256 Outstanding Shares50,020,000Market Cap$2.75 billion Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions What is Emergent Biosolutions' stock symbol? Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS." How will Emergent Biosolutions' stock buyback program work? Emergent Biosolutions declared that its Board of Directors has initiated a share repurchase program on Friday, March 23rd 2018, which permits the company to buyback $50,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its stock is undervalued. How were Emergent Biosolutions' earnings last quarter? Emergent Biosolutions Inc (NYSE:EBS) released its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported $1.07 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.88 by $0.19. The biopharmaceutical company earned $220.20 million during the quarter, compared to analysts' expectations of $208.94 million. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The firm's quarterly revenue was up 118.5% on a year-over-year basis. During the same period last year, the business earned $0.13 earnings per share. View Emergent Biosolutions' Earnings History. When is Emergent Biosolutions' next earnings date? Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Emergent Biosolutions. What price target have analysts set for EBS? 6 analysts have issued 1 year price objectives for Emergent Biosolutions' shares. Their forecasts range from $55.00 to $62.00. On average, they anticipate Emergent Biosolutions' stock price to reach $59.50 in the next year. This suggests a possible upside of 0.4% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions. What is the consensus analysts' recommendation for Emergent Biosolutions? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions. What are Wall Street analysts saying about Emergent Biosolutions stock? Here are some recent quotes from research analysts about Emergent Biosolutions stock: 1. Cantor Fitzgerald analysts commented, ". Post 2Q18, we are reiterating our Overweight rating and 12- month price target of $62. Emergent has successfully established itself as a leader in the biodefense field and has carved out a high-barrier-to-entry niche in that market. We believe the company’s business is a lot more durable than the Street is giving the company credit for. We expect Emergent to extend a number of its current contracts beyond current estimates. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on its products. The company has set a goal of $1B in revenue, which we expect it to reach through the renewal of contracts, pipeline advancements and business development." (8/2/2018) 2. According to Zacks Investment Research, "Emergent’s follow-on contract with the CDC and deals with the BARDA for BioThrax and NuThrax bode well for growth even though performance has been impacted by a delay in the timing of BioThrax deliveries and the delay in the timing of one ACAM2000 shipment. The shift of deliveries to the second quarter impacted both revenue and profitability. We are also positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the company’s cost structure. Shares have outperformed the broader industry in the last one year. However, the company derives the majority of revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is concerning. Moreover, Emergent depends on certain single-source suppliers for key materials and services that are necessary for the manufacture of BioThrax which is concerning." (7/10/2018) Who are some of Emergent Biosolutions' key competitors? Some companies that are related to Emergent Biosolutions include Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR) and Catalent (CTLT). Who are Emergent Biosolutions' key executives? Emergent Biosolutions' management team includes the folowing people: Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 60)Mr. Daniel J. Abdun-Nabi, CEO & Director (Age 63)Mr. Robert G. Kramer Sr., Pres & COO (Age 61)Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 45)Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 47) Has Emergent Biosolutions been receiving favorable news coverage? Headlines about EBS stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Emergent Biosolutions earned a daily sentiment score of 0.20 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 48.11 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Emergent Biosolutions. Who are Emergent Biosolutions' major shareholders? Emergent Biosolutions' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.74%), Renaissance Technologies LLC (4.13%), Dimensional Fund Advisors LP (4.07%), Acadian Asset Management LLC (3.05%), Standard Life Aberdeen plc (2.87%) and Rice Hall James & Associates LLC (2.29%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions. Which institutional investors are selling Emergent Biosolutions stock? EBS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Russell Investments Group Ltd., Acadian Asset Management LLC, Dimensional Fund Advisors LP, LSV Asset Management, Federated Investors Inc. PA, Standard Life Aberdeen plc and Convergence Investment Partners LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions. Which institutional investors are buying Emergent Biosolutions stock? EBS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, FMR LLC, Rice Hall James & Associates LLC, Tributary Capital Management LLC, Meritage Portfolio Management, American Century Companies Inc. and Phocas Financial Corp.. View Insider Buying and Selling for Emergent Biosolutions. How do I buy shares of Emergent Biosolutions? Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Emergent Biosolutions' stock price today? One share of EBS stock can currently be purchased for approximately $59.27. How big of a company is Emergent Biosolutions? Emergent Biosolutions has a market capitalization of $2.75 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent Biosolutions employs 1,256 workers across the globe. How can I contact Emergent Biosolutions? Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at burrowsr[email protected] MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 270 (Vote Outperform)Underperform Votes: 219 (Vote Underperform)Total Votes: 489MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/20/2018 by MarketBeat.com StaffFeatured Article: Dividend Stocks - Are They Right For You?